Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1Phase 1/2 1

Status

Completed 7Unknown 6Recruiting 5Not yet recruiting 5Active not recruiting 2

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Head & Neck 5

Conditions

Pancreatic Neoplasms 54Biliary Tract Neoplasms 23Nasopharyngeal Carcinoma 22Cholangiocarcinoma 22Carcinoma, Non-Small-Cell Lung 22Urinary Bladder Neoplasms 18Breast Neoplasms 18Neoplasm Metastasis 17Lung Neoplasms 14Lymphoma, Large B-Cell, Diffuse 13Colorectal Neoplasms 12Carcinoma, Transitional Cell 12Non-Muscle Invasive Bladder Neoplasms 10Recurrence 8Ovarian Neoplasms 8Triple Negative Breast Neoplasms 7Sarcoma 7Gallbladder Neoplasms 7Neoplasms 6Hodgkin Disease 6Nasopharyngeal Neoplasms 5Bile Duct Neoplasms 5Adenocarcinoma 5Uterine Cervical Neoplasms 4Locally Advanced Pancreatic Cancer 4Endometrial Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Adenocarcinoma 3Osteosarcoma 3Lymphoma 3

Interventions

Gemcitabine 5Cisplatin 5toripalimab 3Radiotherapy, Intensity-Modulated 3Nivolumab 2spartalizumab 1pembrolizumab 1camrelizumab 1Radiotherapy 1Radiation 1Phantoms, Imaging 1Patient Reported Outcome Measures 1Observation 1Magnetic Resonance Spectroscopy 1Interferon beta-1a 1Induction Chemotherapy 1Immunotherapy 1Immunohistochemistry 1Fluorouracil 1Endoscopy 1Carboplatin 1Blood Specimen Collection 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Nasopharyngeal Neoplasms × Gemcitabine × Clear all
NCT06802835 2026-05-11

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 1/2 Recruiting
148 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT06457503 2026-04-06

TRANSPARENT

Coherus Oncology, Inc.

Phase 4 Recruiting
100 enrolled
Head & Neck

Nasopharyngeal Neoplasms

NCT05305131 2025-09-23

Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer

National University Hospital, Singapore

Phase 2 Recruiting
50 enrolled
Head & Neck

Nasopharyngeal Neoplasms

NCT06749899 2025-05-22

QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Sun Yat-sen University

Phase 3 Recruiting
580 enrolled
Head & Neck

Nasopharyngeal Neoplasms

NCT06019130 2024-05-16

NPC-Nivo

German Society for Pediatric Oncology and Hematology GPOH gGmbH

Phase 2 Recruiting
57 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡